REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the company's innovative drug, Telitacicept.

The biotech firm revealed that clinical data from the China Phase III study of Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data, which validates the drug's long-term efficacy, will be presented at the prestigious conference scheduled for October 29 to November 1 in San Francisco, California.

Adding to investor optimism, REMEGEN also highlighted its global exclusive licensing agreement with Pfizer Inc. (formerly Seattle Genetics) during a recent earnings briefing. The agreement, established in August 2021, grants Pfizer the global development and commercialization rights for Disitamab vedotin (RC48) outside REMEGEN's territory. The company confirmed that Pfizer is advancing RC48's overseas clinical trials as planned, potentially opening up significant market opportunities for REMEGEN's innovative therapies.